{
    "Clinical Trial ID": "NCT00320710",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Zoledronic Acid Every (q) 4 Weeks",
        "  Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.",
        "INTERVENTION 2: ",
        "  Zoledronic Acid q 12 Weeks",
        "  Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Female patients  18 years of age. Confirmed breast cancer with bone metastasis. Pretreated with Zometa\u00ae, or Aredia (pamidronate) or all sequential regimens of both, for a minimum of 9 doses;",
        "Exclusion Criteria:",
        "  Abnormal kidney function determined by serum creatinine levels. Current active dental problems including: ongoing infection of the teeth or jawbone; current exposed bone in the mouth; and current or prior diagnosis of osteonecrosis of the jaw.",
        "  Recent (within 8 weeks) or planned dental or jaw surgery (e.g., extraction, implants).",
        "  Diagnosis of metabolic bone disease other than osteoporosis (e.g., Paget's disease of bone).",
        "  Known hypersensitivity to Zometa. Treatment with other investigational drugs within 30 days prior to randomization.",
        "  Other protocol-defined exclusion criteria may have applied."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Proportion of Patients Who Experienced at Least One Skeletal Related Event (SRE)",
        "  An SRE was defined as a pathologic fracture (vertebral and non-vertebral), spinal cord compression, radiation to bone or surgery to bone.",
        "  Time frame: 52 weeks",
        "Results 1: ",
        "  Arm/Group Title: Zoledronic Acid Every (q) 4 Weeks",
        "  Arm/Group Description: Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.",
        "  Overall Number of Participants Analyzed: 200",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of participants  22",
        "Results 2: ",
        "  Arm/Group Title: Zoledronic Acid q 12 Weeks",
        "  Arm/Group Description: Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.",
        "  Overall Number of Participants Analyzed: 203",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of participants  23.2"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 50/198 (25.25%)",
        "  Anaemia 1/198 (0.51%)",
        "  Febrile neutropenia 1/198 (0.51%)",
        "  Leukocytosis 1/198 (0.51%)",
        "  Leukopenia 2/198 (1.01%)",
        "  Neutropenia 1/198 (0.51%)",
        "  Pancytopenia 0/198 (0.00%)",
        "  Atrial fibrillation 0/198 (0.00%)",
        "  Cardiac failure congestive 0/198 (0.00%)",
        "  Palpitations 0/198 (0.00%)",
        "  Pericardial effusion 1/198 (0.51%)",
        "  Supraventricular tachycardia 1/198 (0.51%)",
        "Adverse Events 2:",
        "  Total: 51/202 (25.25%)",
        "  Anaemia 3/202 (1.49%)",
        "  Febrile neutropenia 2/202 (0.99%)",
        "  Leukocytosis 0/202 (0.00%)",
        "  Leukopenia 0/202 (0.00%)",
        "  Neutropenia 0/202 (0.00%)",
        "  Pancytopenia 1/202 (0.50%)",
        "  Atrial fibrillation 1/202 (0.50%)",
        "  Cardiac failure congestive 1/202 (0.50%)",
        "  Palpitations 1/202 (0.50%)",
        "  Pericardial effusion 1/202 (0.50%)",
        "  Supraventricular tachycardia 1/202 (0.50%)"
    ]
}